# RAPD PCR Profile, Antibiotic Resistance, Prevalence ofarmA Gene, and Detection of KPC Enzyme in Klebsiella pneumoniae Isolates

Authors: Arezoo Saadatian Farivar; Jamileh Nowroozi; Gita Eslami; Azar Sabokbar
Journal: Canadian Journal of Infectious Diseases and Medical Microbiology
 (2018)

---

## Abstract

The increasing prevalence of multidrug-resistantKlebsiella pneumoniae strains isolated from hospitals shows the limitation of recent antibiotics used for bacterial eradication. In this study, 81 K. pneumoniae isolates were collected from three hospitals in Tehran. Antibiotic susceptibility test showed the highest rates of resistance to cefotaxim (85.5%) and ceftazidime (78.3%), and the lowest rates of resistance were detected for colistin (16.9%), streptomycin (16.8%), and chloroamphenicol (21.7%). Eleven different resistance patterns were observed. Sixty-six out of 81 isolates (81.5%) were found to be multidrug resistant (MDR), and 35.8% of them belonged to A3 resistance pattern. 7.4% and 66.7% were KPC enzyme and armA gene positive, respectively. RAPD PCR assay of these bacteria showed 5 clusters, 16 single types, and 14 common types, and there was not any correlation between genetic patterns of the isolates and presence of resistance agents. Simultaneous detection of resistance-creating agents could be an important challenge for combination therapy of MDR K. pneumoniae-caused infections.


---

## Body

## 1. Introduction

In the 1980s, gram-negative pathogens were successfully defeated using cephalosporins, carbapenems, and fluoroquinolones [1]. K. pneumoniae is one of the most widespread nosocomial pathogens causing urinary tract infections, bacteremia, and pneumonia in different parts of the world [2, 3]. Extensive use of antibiotics and thereby the development of various resistance mechanisms have led to the emergence of MDR (multidrug resistance) K. pneumoniae [4]. KPC- (Klebsiella pneumoniae carbapenemase-) producing K. pneumoniae strains are the most common carbapenamase-producing pathogens worldwide [5] that have also been reported in Iran in many studies [6–8]. Seventeen different types in the KPC family have been reported to date [9], among which one family is located on a conjugative plasmid that encodes resistance to gentamicin and tobramycin [10]. The armA gene, which is responsible for resistance to the majority of the aminoglycosides and is the most prevalent in Asia [11], was found to be located on the same plasmid of KPC-producing strains reported formerly from Italy [12], China [13], and Poland [14]. Coexistence of the resistance-inducing agents can result in the emerging of MDR K. pneumoniae strains. Epidemiological characterization of MDR K. pneumoniae can help to prevent the spread of resistant strains [15]. RAPD PCR (random amplification of polymorphic DNA PCR) is a simple, rapid, inexpensive, and widely used typing method which does not require advanced knowledge of DNA sequences of the target organism. RAPD typing has been successfully employed for epidemiological analysis of many bacteria [16] as well as clinical isolates of K. pneumonia [17].This study aimed to detect the RAPD PCR fingerprint, antibiotic resistance patterns, and the presence ofarmA gene in clinical KPC-producing isolates and nonproducing isolates of K. pneumoniae.


## 2. Materials and Methods

### 2.1. Bacterial Collection

From September 2015 to March 2016, clinical samples were collected from both inpatients and outpatients attending three hospitals in Tehran, Iran. The samples were transferred to the microbiology laboratory, and biochemical tests were performed to identifyK. pneumoniae. The pure isolates were stored at −20°C in Trypticase soy broth containing 20% glycerol.


### 2.2. Susceptibility Testing and Phenotypic Detection of KPC

The antimicrobial susceptibility test was conducted using the Kirby–Bauer disk diffusion method on Mueller–Hinton agar (Merck, Germany). Also, for colistin-resistant isolates, MIC was determined through a broth microdilution method, according to the Clinical and Laboratory Standard Institute (CLSI) guidelines. The isolates were tested for susceptibility to the following 16 antimicrobial agents (MAST Group, Merseyside, UK): ofloxacin (OFX, 5μg), ciprofloxacin (CIP, 5 μg), norfloxacin (NOR, 10 μg), gentamicin (GM, 10 μg), amikacin (AK, 30 μg), streptomycin (HLS, 10 μg), tobramycin (TOB, 10 μg), kanamycin (K, 30 μg), ticarcillin (TIC, 75 μg), cefotaxim (CTX, 30 μg), ceftazidime (CAZ, 30 μg), azetreonam (ATM, 30 μg), imipenem (IMI, 10 μg), trimethoprim (TR, 5 μg), chloramphenicol (C, 30 μg), and colistin (CO, 10 μg). Escherichia coli ATCC 25922 was used as a control strain. Also, detection of KPC enzyme was performed by the modified Hodge test [18].


### 2.3. Detection of armA Gene

Bacteria were cultured in Luria–Bertani (LB) broth medium and were incubated overnight at 37°C. DNA was extracted fromK. pneumoniae isolates by using Genomic DNA Isolation Kit (Global Gene Network Bio, cat. no. k-3000, South Korea) according to the manufacturer’s instruction. The presence of armA gene was evaluated using PCR technique with the armA-F: TCGGAACTTAAAGACGACGA and armA-R: CCATTCCCTTCTCCTTTCCA (designed in this study) sequences. The PCR product was analyzed by electrophoresis in a 1% (W/V) agarose gel in TBE buffer at 95 V for 45 min, stained with ethidium bromide, and observed under UV lighting using Gel Doc. Then, DNA sequencing was performed by Bioneer Company (Korea), blasted in NCBI, and analyzed by Finch TV software.


### 2.4. RAPD PCR

Molecular typing ofK. pneumoniae isolates was performed using RAPD PCR analysis with the primer 640 (CGTGGGGCCT) (Faza Biotech, Tehran, Iran). Reaction mixtures (25 µl) contained: 12.5 µl (Exprime Taq Premix (2X) Mastermix (Global Gene Network Bio, cat. no. G-5000)), 7.5 µl Distilled water, 200 pmol of primer, and 3 µl DNA template. The program used was as follows: 5 min at 94°C followed by 36 cycles of 1 min at 94°C, 1 min at 36°C, and 2 min at 72°C followed by a final extension at 72°C for 9 min. PCR products were then electrophoresed on 1% agarose gels and visualized by ethidium bromide staining. To determine the similarity rate among the isolates, they were analyzed by the unweighted pair-group method with arithmetic mean (UPGMA) using GelClust software.


## 2.1. Bacterial Collection

From September 2015 to March 2016, clinical samples were collected from both inpatients and outpatients attending three hospitals in Tehran, Iran. The samples were transferred to the microbiology laboratory, and biochemical tests were performed to identifyK. pneumoniae. The pure isolates were stored at −20°C in Trypticase soy broth containing 20% glycerol.


## 2.2. Susceptibility Testing and Phenotypic Detection of KPC

The antimicrobial susceptibility test was conducted using the Kirby–Bauer disk diffusion method on Mueller–Hinton agar (Merck, Germany). Also, for colistin-resistant isolates, MIC was determined through a broth microdilution method, according to the Clinical and Laboratory Standard Institute (CLSI) guidelines. The isolates were tested for susceptibility to the following 16 antimicrobial agents (MAST Group, Merseyside, UK): ofloxacin (OFX, 5μg), ciprofloxacin (CIP, 5 μg), norfloxacin (NOR, 10 μg), gentamicin (GM, 10 μg), amikacin (AK, 30 μg), streptomycin (HLS, 10 μg), tobramycin (TOB, 10 μg), kanamycin (K, 30 μg), ticarcillin (TIC, 75 μg), cefotaxim (CTX, 30 μg), ceftazidime (CAZ, 30 μg), azetreonam (ATM, 30 μg), imipenem (IMI, 10 μg), trimethoprim (TR, 5 μg), chloramphenicol (C, 30 μg), and colistin (CO, 10 μg). Escherichia coli ATCC 25922 was used as a control strain. Also, detection of KPC enzyme was performed by the modified Hodge test [18].


## 2.3. Detection of armA Gene

Bacteria were cultured in Luria–Bertani (LB) broth medium and were incubated overnight at 37°C. DNA was extracted fromK. pneumoniae isolates by using Genomic DNA Isolation Kit (Global Gene Network Bio, cat. no. k-3000, South Korea) according to the manufacturer’s instruction. The presence of armA gene was evaluated using PCR technique with the armA-F: TCGGAACTTAAAGACGACGA and armA-R: CCATTCCCTTCTCCTTTCCA (designed in this study) sequences. The PCR product was analyzed by electrophoresis in a 1% (W/V) agarose gel in TBE buffer at 95 V for 45 min, stained with ethidium bromide, and observed under UV lighting using Gel Doc. Then, DNA sequencing was performed by Bioneer Company (Korea), blasted in NCBI, and analyzed by Finch TV software.


## 2.4. RAPD PCR

Molecular typing ofK. pneumoniae isolates was performed using RAPD PCR analysis with the primer 640 (CGTGGGGCCT) (Faza Biotech, Tehran, Iran). Reaction mixtures (25 µl) contained: 12.5 µl (Exprime Taq Premix (2X) Mastermix (Global Gene Network Bio, cat. no. G-5000)), 7.5 µl Distilled water, 200 pmol of primer, and 3 µl DNA template. The program used was as follows: 5 min at 94°C followed by 36 cycles of 1 min at 94°C, 1 min at 36°C, and 2 min at 72°C followed by a final extension at 72°C for 9 min. PCR products were then electrophoresed on 1% agarose gels and visualized by ethidium bromide staining. To determine the similarity rate among the isolates, they were analyzed by the unweighted pair-group method with arithmetic mean (UPGMA) using GelClust software.


## 3. Results

### 3.1. Bacterial Isolation

Eighty-oneK. pneumoniae were isolated from the patients (44 males and 37 females). Samples were isolated from different clinical specimens including urine, 49 (60.5%); blood cultures, 16 (19.7%); wounds, 5 (6.2%); sputum, 4 (5%); intra-abdominal, 3 (3.7%), and others 4 (5%). The hospital ward distribution was as follows: pediatric ward, 24 (29.6%); outpatient, 18 (22.2%); intensive care unit, 10 (12.3%); surgical unit, 6 (7.4%); infection unit, 2 (2.5%); and others, 21 (26%).


### 3.2. Determination of Antibiotic Resistance and KPC Enzyme Detection

Antibiogram showed that the resistance rates of the isolates were as follows: ofloxacin 65%, ciprofloxacin 68.7%, norfloxacin 66.3%, gentamicin 66.3%, amikacin 51.8%, tobramycin 56.7%, kanamycin 79.5%, ticarcillin 82%, streptomycin 16.9%, cefotaxim 85.5%, ceftazidime 78.3%, azetreonam 79.5%, imipenem 45.8%, trimethoprim 74.7%, chloramphenicol 21.7%, and colistin 16.9%. One colistin-resistant isolate had a MIC of 8µg/ml, and the other all had MIC values of 4 µg/ml. All the colistin-resistant isolates except one of them belonged to one hospital. Five colistin-resistant K. pneumoniae exhibited resistance to imipenem of which one was positive for KPC production. The antibiotic resistance pattern of the isolates is shown in Table 1. The highest rate of the resistance belonged to the A9 pattern (64.2%) which found to be resistant to three flouroquinolons. Also, the lowest rate of resistance belonged to the A4 pattern (4.9%) which was resistant to ciprofloxacin, ofloxacin, norfloxacin, imipenem, amikacin, and colistin. MDR is generally determined as resistance to three or more classes of antibiotics [19]. In the present study, 66 out of 81 isolates were resistant to 3 or more classes of antibiotics; thereby, 81.5% of the isolates were found to be MDR. Also, the modified Hodge test showed that 6 isolates (7.4%) were positive for KPC production with 3 resistance patterns (Table 2).Table 1
Antibiotic resistance patterns.
Resistance pattern number
Number of isolates (%)
Antibiotics
A1
11 (13.6)
OFX, NOR, CIP, IMI, K, GM, AK, TOB, HLS
A2
19 (23.4)
OFX, NOR, CIP, IMI, GM, AK, TOB, K
A3
29 (35.8)
OFX, NOR, CIP, IMI, K, GM
A4
4 (4.9)
CIP, OFX, NOR, IMI, AK, CO
A5
12 (14.8)
AK, GM, TOB, K, HLS
A6
25 (30.9)
CIP, OFX, NOR, IMI, AK
A7
33 (40.7)
CIP, OFX, NOR, IMI
A8
30 (37)
CIP, OFX, NOR, AK
A9
52 (64.2)
CIP, OFX, NOR
A10
11 (13.6)
TR, TIC, C
A11
25 (30.9)
IMI, AK
OFX: ofloxacin; NOR: norfloxacin; CIP: ciprofloxacin; IMI: imipenem; GM: gentamicin; AK: amikacin; TOB: tobramycin; HLS: streptomycin; K: kanamycin; CO: colistin; TR: trimethoprim; TIC: ticarcillin; C: chloramphenicol.Table 2
Antibiotic resistance patterns and presence ofarmA gene.
Isolate name
Resistance pattern
armA
1
OFX, NOR, CIP, IMI, K, GM, AK, TOB, HLS
+
2
OFX, NOR, CIP, IMI, K, GM, AK, TOB
+
3
OFX, NOR, CIP, IMI, K, GM, AK, TOB
−
4
OFX, NOR, CIP, IMI, K, GM
−
5
OFX, NOR, CIP, IMI, K, GM
+
6
OFX, NOR, CIP, IMI, K, GM
+
OFX: ofloxacin; NOR: norfloxacin; CIP: ciprofloxacin; IMI: imipenem; K: kanamycin; GM: gentamicin; AK: amikacin; TOB: tobramycin; HLS: streptomycin.


### 3.3. Molecular Detection

The PCR showed that 54 isolates (66.7%) of the isolates hadarmA gene. Aminoglycoside resistance patterns in armA positive isolates were presented in Table 3.Table 3
Aminoglycoside resistance inarmA positive isolates.
Aminoglycosides
Resistant number (%)
armA+ number (%)
Kanamycin
66 (79.5)
46 (69.7)
Tobramycin
47 (56.7)
32 (68)
Gentamicin
55 (66.3)
38 (69)
Amikacin
43 (51.8)
32 (74.4)
Streptomycin
14 (16.9)
12 (87.7)


### 3.4. RAPD PCR

Genetic analysis of RAPD showed 30 distinct patterns from D1 to D30, as 5 distinct clusters (Figure1). The information of isolates is shown in Table 4. The isolates were considered as the same pattern if the level of similarity was ≥85%. The numbers of the isolates in each cluster (from cluster 1 to 5) were 18, 19, 14, 26, and 4, respectively. The highest redundancy belonged to pattern D1, D8, and D20. There was not any correlation between genetic patterns of the isolates and presence of armA gene or KPC production. The isolates which showed 100% similarity, belonging to different clusters, all found to have armA gene.Figure 1
Cluster analysis ofKlebsiella pneumoniae based on RAPD typing.Table 4
Analysis of strains with their RAPD profiles.
Isolate number
armA
KPC
Date
Origin
Department
Hospital
RAPD pattern
1
−
−
February 2016
Urine
Gynecology and obstetrician
A
D1
2
−
−
February 2016
Urine
Outpatient
A
D1
3
−
−
February 2016
Urine
Outpatient
A
D1
4
−
−
February 2016
Urine
Laparoscopy
A
D1
5
−
−
February 2016
Urine
Outpatient
A
D1
6
+
−
September 2015
Wound
Others
B
D1
7
−
−
February 2016
Urine
Outpatient
A
D1
8
+
−
October 2015
Blood
Pediatric
C
D1
9
−
−
February 2016
Urine
Rheumatology
A
D1
10
+
−
March 2016
Urine
Nephrology
A
D1
11
−
−
February 2016
Urine
Others
A
D2
12
+
−
December 2015
Blood
Hematology
B
D3
13
+
−
January 2015
Wound
Surgery
B
D3
14
+
−
January 2015
Urine
Pediatric
C
D3
15
−
+
November 2015
Urine
Outpatient
B
D4
16
−
−
November 2015
Blood
Infectious
B
D4
17
+
−
September 2015
Intraabdominal
Gastrointestinal
B
D5
18
+
+
September 2015
Sputum
ICU
B
D5
19
−
−
February 2016
Urine
Cancer
A
D6
20
+
−
October 2015
Sputum
Bone marrow transplantation
B
D7
21
−
−
February 2016
Urine
Dermatology
A
D8
22
−
+
February 2016
Urine
Cardiology
A
D8
23
+
−
January 2015
Blood
Pediatric
C
D8
24
−
−
March 2016
Urine
Outpatient
A
D8
25
−
−
March 2016
Urine
Outpatient
A
D8
26
+
−
January 2015
Blood
ICU
B
D8
27
−
−
January 2015
Sputum
ICU
B
D8
28
+
−
December 2015
Urine
Outpatient
B
D8
29
+
−
December 2015
Blood
Pediatric
C
D8
30
+
−
December 2015
Blood
Pediatric
C
D8
31
+
−
October 2015
Wound
Surgery
B
D9
32
+
−
November 2015
Intraabdominal
Cancer
B
D10
33
−
−
October 2015
Others
NICU
B
D10
34
+
−
November 2015
Blood
Pediatric
C
D10
35
+
−
December 2015
Urine
Pediatric
C
D11
36
+
−
September 2015
Sputum
ICU
B
D12
37
+
−
October 2015
Wound
Surgery
B
D12
38
+
−
March 2016
Urine
ICU
A
D13
39
+
+
March 2016
Urine
Others
A
D13
40
+
−
January 2015
Blood
Pediatric
C
D13
41
+
−
February 2016
Urine
Outpatient
A
D14
42
+
−
January 2015
Others
Pediatric
C
D14
43
+
−
January 2015
Urine
Pediatric
C
D14
44
+
−
December 2015
Others
Outpatient
B
D14
45
+
+
December 2015
Urine
Pediatric
C
D14
46
+
−
December 2015
Blood
Pediatric
C
D14
47
−
−
September 2015
Urine
Surgery
B
D15
48
−
−
February 2016
Urine
Outpatient
A
D16
49
+
−
October 2015
Urine
Pediatric
C
D17
50
+
−
November 2015
Urine
Endocrinology
B
D18
51
+
−
November 2015
Blood
Pediatric
C
D18
52
−
−
March 2016
Urine
Cardiology
A
D19
53
+
−
March 2016
Urine
Others
A
D19
54
−
−
March 2016
Urine
Pediatric
A
D19
55
−
−
March 2016
Urine
Outpatient
A
D19
56
−
−
January 2015
Urine
Pediatric
C
D19
57
−
−
February 2016
Urine
Pediatric
A
D20
58
−
−
February 2016
Urine
Surgery
A
D20
59
−
−
February 2016
Urine
ICU
A
D20
60
−
−
February 2016
Urine
Others
A
D20
61
+
−
November 2015
Urine
Pediatric
C
D20
62
+
−
November 2015
Urine
Outpatient
B
D20
63
+
−
January 2015
Urine
Pediatric
C
D20
64
+
−
November 2015
Blood
Outpatient
B
D20
65
+
−
January 2015
Urine
Pediatric
C
D20
66
+
−
January 2015
Others
Outpatient
B
D20
67
+
−
September 2015
Wound
Others
B
D21
68
+
−
November 2015
Blood
Hematology
B
D22
69
+
−
November 2015
Blood
Pediatric
C
D22
70
+
−
September 2015
Urine
NICU
B
D22
71
+
−
September 2015
Urine
Pediatric
C
D22
72
+
−
March 2016
Urine
Surgery
A
D23
73
+
−
March 2016
Urine
Cardiology
A
D24
74
+
−
December 2015
Blood
NICU
B
D25
75
−
−
February 2016
Urine
Pediatric
A
D26
76
+
−
October 2015
Urine
Outpatient
B
D27
77
+
−
December 2015
Urine
ICU
B
D28
78
−
−
February 2016
Urine
Outpatient
A
D29
79
−
−
February 2016
Urine
Outpatient
A
D29
80
+
+
January 2015
Intraabdominal
Infectious
B
D29
81
+
−
November 2015
Blood
Pediatric
C
D30


## 3.1. Bacterial Isolation

Eighty-oneK. pneumoniae were isolated from the patients (44 males and 37 females). Samples were isolated from different clinical specimens including urine, 49 (60.5%); blood cultures, 16 (19.7%); wounds, 5 (6.2%); sputum, 4 (5%); intra-abdominal, 3 (3.7%), and others 4 (5%). The hospital ward distribution was as follows: pediatric ward, 24 (29.6%); outpatient, 18 (22.2%); intensive care unit, 10 (12.3%); surgical unit, 6 (7.4%); infection unit, 2 (2.5%); and others, 21 (26%).


## 3.2. Determination of Antibiotic Resistance and KPC Enzyme Detection

Antibiogram showed that the resistance rates of the isolates were as follows: ofloxacin 65%, ciprofloxacin 68.7%, norfloxacin 66.3%, gentamicin 66.3%, amikacin 51.8%, tobramycin 56.7%, kanamycin 79.5%, ticarcillin 82%, streptomycin 16.9%, cefotaxim 85.5%, ceftazidime 78.3%, azetreonam 79.5%, imipenem 45.8%, trimethoprim 74.7%, chloramphenicol 21.7%, and colistin 16.9%. One colistin-resistant isolate had a MIC of 8µg/ml, and the other all had MIC values of 4 µg/ml. All the colistin-resistant isolates except one of them belonged to one hospital. Five colistin-resistant K. pneumoniae exhibited resistance to imipenem of which one was positive for KPC production. The antibiotic resistance pattern of the isolates is shown in Table 1. The highest rate of the resistance belonged to the A9 pattern (64.2%) which found to be resistant to three flouroquinolons. Also, the lowest rate of resistance belonged to the A4 pattern (4.9%) which was resistant to ciprofloxacin, ofloxacin, norfloxacin, imipenem, amikacin, and colistin. MDR is generally determined as resistance to three or more classes of antibiotics [19]. In the present study, 66 out of 81 isolates were resistant to 3 or more classes of antibiotics; thereby, 81.5% of the isolates were found to be MDR. Also, the modified Hodge test showed that 6 isolates (7.4%) were positive for KPC production with 3 resistance patterns (Table 2).Table 1
Antibiotic resistance patterns.
Resistance pattern number
Number of isolates (%)
Antibiotics
A1
11 (13.6)
OFX, NOR, CIP, IMI, K, GM, AK, TOB, HLS
A2
19 (23.4)
OFX, NOR, CIP, IMI, GM, AK, TOB, K
A3
29 (35.8)
OFX, NOR, CIP, IMI, K, GM
A4
4 (4.9)
CIP, OFX, NOR, IMI, AK, CO
A5
12 (14.8)
AK, GM, TOB, K, HLS
A6
25 (30.9)
CIP, OFX, NOR, IMI, AK
A7
33 (40.7)
CIP, OFX, NOR, IMI
A8
30 (37)
CIP, OFX, NOR, AK
A9
52 (64.2)
CIP, OFX, NOR
A10
11 (13.6)
TR, TIC, C
A11
25 (30.9)
IMI, AK
OFX: ofloxacin; NOR: norfloxacin; CIP: ciprofloxacin; IMI: imipenem; GM: gentamicin; AK: amikacin; TOB: tobramycin; HLS: streptomycin; K: kanamycin; CO: colistin; TR: trimethoprim; TIC: ticarcillin; C: chloramphenicol.Table 2
Antibiotic resistance patterns and presence ofarmA gene.
Isolate name
Resistance pattern
armA
1
OFX, NOR, CIP, IMI, K, GM, AK, TOB, HLS
+
2
OFX, NOR, CIP, IMI, K, GM, AK, TOB
+
3
OFX, NOR, CIP, IMI, K, GM, AK, TOB
−
4
OFX, NOR, CIP, IMI, K, GM
−
5
OFX, NOR, CIP, IMI, K, GM
+
6
OFX, NOR, CIP, IMI, K, GM
+
OFX: ofloxacin; NOR: norfloxacin; CIP: ciprofloxacin; IMI: imipenem; K: kanamycin; GM: gentamicin; AK: amikacin; TOB: tobramycin; HLS: streptomycin.


## 3.3. Molecular Detection

The PCR showed that 54 isolates (66.7%) of the isolates hadarmA gene. Aminoglycoside resistance patterns in armA positive isolates were presented in Table 3.Table 3
Aminoglycoside resistance inarmA positive isolates.
Aminoglycosides
Resistant number (%)
armA+ number (%)
Kanamycin
66 (79.5)
46 (69.7)
Tobramycin
47 (56.7)
32 (68)
Gentamicin
55 (66.3)
38 (69)
Amikacin
43 (51.8)
32 (74.4)
Streptomycin
14 (16.9)
12 (87.7)


## 3.4. RAPD PCR

Genetic analysis of RAPD showed 30 distinct patterns from D1 to D30, as 5 distinct clusters (Figure1). The information of isolates is shown in Table 4. The isolates were considered as the same pattern if the level of similarity was ≥85%. The numbers of the isolates in each cluster (from cluster 1 to 5) were 18, 19, 14, 26, and 4, respectively. The highest redundancy belonged to pattern D1, D8, and D20. There was not any correlation between genetic patterns of the isolates and presence of armA gene or KPC production. The isolates which showed 100% similarity, belonging to different clusters, all found to have armA gene.Figure 1
Cluster analysis ofKlebsiella pneumoniae based on RAPD typing.Table 4
Analysis of strains with their RAPD profiles.
Isolate number
armA
KPC
Date
Origin
Department
Hospital
RAPD pattern
1
−
−
February 2016
Urine
Gynecology and obstetrician
A
D1
2
−
−
February 2016
Urine
Outpatient
A
D1
3
−
−
February 2016
Urine
Outpatient
A
D1
4
−
−
February 2016
Urine
Laparoscopy
A
D1
5
−
−
February 2016
Urine
Outpatient
A
D1
6
+
−
September 2015
Wound
Others
B
D1
7
−
−
February 2016
Urine
Outpatient
A
D1
8
+
−
October 2015
Blood
Pediatric
C
D1
9
−
−
February 2016
Urine
Rheumatology
A
D1
10
+
−
March 2016
Urine
Nephrology
A
D1
11
−
−
February 2016
Urine
Others
A
D2
12
+
−
December 2015
Blood
Hematology
B
D3
13
+
−
January 2015
Wound
Surgery
B
D3
14
+
−
January 2015
Urine
Pediatric
C
D3
15
−
+
November 2015
Urine
Outpatient
B
D4
16
−
−
November 2015
Blood
Infectious
B
D4
17
+
−
September 2015
Intraabdominal
Gastrointestinal
B
D5
18
+
+
September 2015
Sputum
ICU
B
D5
19
−
−
February 2016
Urine
Cancer
A
D6
20
+
−
October 2015
Sputum
Bone marrow transplantation
B
D7
21
−
−
February 2016
Urine
Dermatology
A
D8
22
−
+
February 2016
Urine
Cardiology
A
D8
23
+
−
January 2015
Blood
Pediatric
C
D8
24
−
−
March 2016
Urine
Outpatient
A
D8
25
−
−
March 2016
Urine
Outpatient
A
D8
26
+
−
January 2015
Blood
ICU
B
D8
27
−
−
January 2015
Sputum
ICU
B
D8
28
+
−
December 2015
Urine
Outpatient
B
D8
29
+
−
December 2015
Blood
Pediatric
C
D8
30
+
−
December 2015
Blood
Pediatric
C
D8
31
+
−
October 2015
Wound
Surgery
B
D9
32
+
−
November 2015
Intraabdominal
Cancer
B
D10
33
−
−
October 2015
Others
NICU
B
D10
34
+
−
November 2015
Blood
Pediatric
C
D10
35
+
−
December 2015
Urine
Pediatric
C
D11
36
+
−
September 2015
Sputum
ICU
B
D12
37
+
−
October 2015
Wound
Surgery
B
D12
38
+
−
March 2016
Urine
ICU
A
D13
39
+
+
March 2016
Urine
Others
A
D13
40
+
−
January 2015
Blood
Pediatric
C
D13
41
+
−
February 2016
Urine
Outpatient
A
D14
42
+
−
January 2015
Others
Pediatric
C
D14
43
+
−
January 2015
Urine
Pediatric
C
D14
44
+
−
December 2015
Others
Outpatient
B
D14
45
+
+
December 2015
Urine
Pediatric
C
D14
46
+
−
December 2015
Blood
Pediatric
C
D14
47
−
−
September 2015
Urine
Surgery
B
D15
48
−
−
February 2016
Urine
Outpatient
A
D16
49
+
−
October 2015
Urine
Pediatric
C
D17
50
+
−
November 2015
Urine
Endocrinology
B
D18
51
+
−
November 2015
Blood
Pediatric
C
D18
52
−
−
March 2016
Urine
Cardiology
A
D19
53
+
−
March 2016
Urine
Others
A
D19
54
−
−
March 2016
Urine
Pediatric
A
D19
55
−
−
March 2016
Urine
Outpatient
A
D19
56
−
−
January 2015
Urine
Pediatric
C
D19
57
−
−
February 2016
Urine
Pediatric
A
D20
58
−
−
February 2016
Urine
Surgery
A
D20
59
−
−
February 2016
Urine
ICU
A
D20
60
−
−
February 2016
Urine
Others
A
D20
61
+
−
November 2015
Urine
Pediatric
C
D20
62
+
−
November 2015
Urine
Outpatient
B
D20
63
+
−
January 2015
Urine
Pediatric
C
D20
64
+
−
November 2015
Blood
Outpatient
B
D20
65
+
−
January 2015
Urine
Pediatric
C
D20
66
+
−
January 2015
Others
Outpatient
B
D20
67
+
−
September 2015
Wound
Others
B
D21
68
+
−
November 2015
Blood
Hematology
B
D22
69
+
−
November 2015
Blood
Pediatric
C
D22
70
+
−
September 2015
Urine
NICU
B
D22
71
+
−
September 2015
Urine
Pediatric
C
D22
72
+
−
March 2016
Urine
Surgery
A
D23
73
+
−
March 2016
Urine
Cardiology
A
D24
74
+
−
December 2015
Blood
NICU
B
D25
75
−
−
February 2016
Urine
Pediatric
A
D26
76
+
−
October 2015
Urine
Outpatient
B
D27
77
+
−
December 2015
Urine
ICU
B
D28
78
−
−
February 2016
Urine
Outpatient
A
D29
79
−
−
February 2016
Urine
Outpatient
A
D29
80
+
+
January 2015
Intraabdominal
Infectious
B
D29
81
+
−
November 2015
Blood
Pediatric
C
D30


## 4. Discussion

In the present study, 81K. pneumoniae were isolated from clinical samples. Antibiotic resistance patterns and their relationships among different clonal isolates were investigated. Eleven antibiotic patterns were found (A1–A11), showing much diversity in the resistance patterns. In the study by Hassan et al. [16] and Ben-Hamouda et al. [17], different antibiotic resistance patterns were reported, too [20]. In the present study, 81.5% were MDR. The presence of multidrug resistance community acquired K. pneumoniae highlights the need for accurate planning to control and prevent of the dissemination of MDR strains. Most of the KPC-producing isolates harbored armA gene and were resistant to carbapenems, aminoglycosides, and fluoroquinolones. According to our previous study, Real Time PCR showed an increased expression level of OqxAB and AcrAB efflux pumps in fluoroquinolone-resistant isolates in comparison with the sensitive ones (data not shown). So, the role of efflux pump in creating fluoroquinolone-resistant strains could be identified in these isolates [21]. Also, the aminoglycoside resistance rates suggested 16S rRNA methylase activity. In the present study, approximately 70% of the aminoglycoside-resistant strains carried the armA gene as Zhou et al. reported [22]. Therefore, some of these K. pneumoniae isolates have three features of resistance: KPC, efflux pumps, and armA gene. So they can be resistant to fluoroquinolones, cephalosporins, carbapenems and a spectrum of aminoglycosides as well. These strains can turn out to an important challenge for community and hospital officials by disseminating among the patients in hospitals and making the treatment process more difficult. Coexistence of the active efflux pump, armA gene, and KPC enzymes in K. pneumoniae can help to resist against the combination therapy. This hypothesis is also recommended by Zacharczuk et al. [14] and Jiang et al. [13] who observed KPC production and armA gene in clinical isolates of K. pneumoniae.Furthermore, about 17% of the isolates were resistant to colistin, among which all but one isolate had MIC 4µg/ml. Although colistin-resistant isolates were related to five different clusters, 42.9% of them belonged only to the fourth cluster from one hospital, indicating a genetically specific circulating cluster. Colistin is considered as effective treatment against MDR and carbapenem-resistant bacteria, such as K. pneumoniae, but resistance to this agent has begun to emerge. So, more studies to determine the best treatment for infections caused by resistant K. pneumoniae are needed. In the present study, genotyping analysis showed different genetic patterns among pathogenic K. pneumoniae isolates. Lim et al. [23], Ben-Hamouda et al. [17], Pai et al. [24], and Eftekhar and Nouri [25] performed separately the genotyping of clinical K. pneumoniae strains and showed that they were genetically diverse and heterogeneous. Therefore, this tool has got the ability to identify related and unrelated isolates. The correlation between the antibiotic resistance patterns and RAPD analysis demonstrated that different genetic patterns had different antibiotyping profiles. Also, KPC-producing K. pneumoniae were found to belong to different clusters, and the results of RAPD PCR implicated that there is no correlation between the genetic patterns and presence of armA gene or KPC-producing K. pneumoniae, as Ma et al. [26] reported that nonclonally spread of ESBL-producing K. pneumoniae strains with armA or rmtB mediates aminoglycoside resistance. It seems that because most resistance genes are carried by the mobile genetic elements, they can easily transmit among the bacteria.Of importance, the low number of the isolates was one of our limitations. Collecting more clinical isolates, using more powerful discriminating typing methods such as PFGE and analysis ofarmA and blakpc genes’ expression level may improve the quality of our results in the following studies.


## 5. Conclusion

Although fluoroquinolones seem to be a good choice for treatingKlebsiella infections, several studies have shown increasing resistance of K. pneumoniae isolates to these agents. Aminoglycosides have been considered as an adequate therapeutic against both gram-negative and gram-positive pathogens and also combination therapy with β-lactams and aminoglycosides is well accepted for the treatment of the systemic infections caused by K. pneumoniae, so simultaneous detection of resistance creating agents to fluoroquinolones, β-lactams, and aminoglycosides in these strains is of clinical importance. Emphasis on the suitable use of antibiotics, effective infection control measures, and identification of antibiotic resistance mechanisms by molecular procedures are necessary to reduce the incidence of infections caused by antibiotic-resistant organisms.



---

*Source: 6183162-2018-02-04.xml*